Title : A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.

Pub. Date : 2016 Mar 1

PMID : 26581242






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 After a single dose, ralimetinib inhibited p38 MAPK-induced phosphorylation of MAPKAP-K2 in peripheral blood mononuclear cells. Ralimetinib MAPK activated protein kinase 2 Homo sapiens